Dishman

Dishman Pharmaceuticals and Chemicals has received Establishment Inspection Report from the US health regulator for three of its facilities.

Here's how small cap stocks opened on December 20

Here's how small cap stocks opened on December 20

Check out: Buzzing small cap stocks on October 17

Here's how small cap stocks opened on October 17

I-T survey for Rs 42cr land deal; will take action: Dishman

The income tax department's surveyed Dishman Pharma's premises over the weekend for taxation issues in a Rs 42 crore land deal involving Dishman SEZ and Dishman Pharma.

Check out: Buzzing small cap stocks on October 9

Here's how small cap stocks opened on October 9

Check out: Buzzing small cap stocks on October 7

Here's how small cap stocks opened on October 7

Buzzing small cap stocks open on September 27

Here's how small cap stocks opened on September 27

Small cap stocks: Top movers on September 24

Here's how small cap stocks opened on September 24

Which small cap stocks fared well on September 20?

Which small cap stocks fared well on September 20?

Check out: Buzzing small cap stocks on September 6

Here's how small cap stocks opened on September 6

Buzzing small cap stocks on September 4

Here's how small cap stocks open on September 4

Buy SBI around Rs 2060, says Baliga

Ambareesh Baliga, Market Expert advice traders to buy SBI around Rs 2060.

India will remain a branded drug market for many more yrs

UR Associates has come out with its report on pharma sector.

Dishman Pharma expects 25% growth in FY13

Dishman Pharmaceuticals posted a 13.24% topline growth in the fourth quarter of FY12 and reported a consolidated net profit of Rs 312.94 million for the quarter ended 31 March, 2012, up 37.30% from Rs 227.92 million in the corresponding quarter last year.

Pharma stocks results preview for Q3FY12: KRChoksey

KRChoksey has come with its December quarterly earning estimates for Pharma sector. According to the research firm, Q3FY12 is expected to be a strong quarter in terms of top-line growth mainly due to improved performance in the Indian pharmaceutical market, launch of limited competitive products in the US market & rupee depreciation.

Dishman Sept qtr PAT seen down 50% at Rs 15 cr: KR Choksey

KR Choksey has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Dishman Pharma September quarter net sales are expected to go up by 9% at Rs 254 crore, year-on-year, (YoY) basis.

Dishman Sept qtr PAT seen up 21% at Rs 10cr: Dolat Capital

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Dishman September quarter net sales are expected to go up by 15.1% at Rs 245 crore, year-on-year, (YoY) basis.